Collin is a Scientist at EpigenDx in product and business development. He graduated from the Pennsylvania State University in 2023 with his Ph.D. in Plant Biology with a focus in genetics, specifically in the accumulation and biogenesis of microRNAs and secondary small interfering RNAs.
Backed by his expertise in molecular diagnostics, molecularly targeted drug discovery and development, biochemistry and regulatory compliance, Rob Fraser drives the innovation behind Molecular You's multi-omic AI-powered analytics platform. Under his direction, Molecular You has established an affordable, comprehensive method of measuring hundreds of biomarkers from a single blood sample, and a LLM and ML model to incorporate the world's leading scientific literature and collected data to accurately predict individual and population health risks.
Previously, as the Chief Operating Officer of the Personalized Medicine Initiative, Rob supported the establishment of six new companies including Molecular You. Rob has also been involved in leading drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD.
Dr. Bloom is an internationally recognized pathologist with expertise in breast disease, digital pathology, immunohistochemistry and molecular pathology. He started his career at Rush University where he served several roles, including Director of Laboratory Operation and the Chief Information Officer for the Rush Cancer Institute. Dr. Bloom was instrumental in bringing digital pathology and image analysis tools to the clinic. Other positions include Chief Medical Officer (CMO) of Clarient. CMO for In-vitro Diagnostics at GE Healthcare, President and head of oncology and immunotherapy at Human Longevity and the CMO at RealmDx. Currently, he heads Pathology for Nucleai.
Ian Pike is the Chief Scientific Officer at Proteome Sciences and has over 30 years’ experience working in the diagnostics and biotechnology sectors. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high-quality service.
Dr. Rao works at the intersection of genomics and image informatics, across biological scale (cells, tissue and organ). He is interested in developing multi-modal decision algorithms that link and integrate various measurements (imaging, genomics etc) to characterize disease. His algorithms for phenotypic measurements encompass data from 2D/3D microscopy, radiology and histopathology. He is also interested in methodological aspects of genomic analysis and image assessment. In the context of these investigations, Dr. Rao collaborates with clinicians, biologists, engineers and data scientists.
Jim Kean is a senior technology executive with an innovative career focused on making healthcare easier. Kean has had multiple exits with health technology companies, and has also spent time as a senior executive at Blue Cross Blue Shield.
Jim Kean founded Sapient Health Network that later merged to form the consumer-facing side of WebMD. He exited the company turning a $5m investment into $187m in 3.5 years. In 2010, he launched WellnessFX which he sold to Thorne (THRN) in 2013 for $25m.
Kareem Barghouti, CEO, earned a B.S. in Biological Sciences from UC Irvine and an MBA from Duke University, specializing in Healthcare Sector Management. With a background in Strategy & Operations and Sales & Marketing, he was an early employee at Wildfire Interactive, acquired by Google for $450M. During his 5 years at Google, he accelerated in leadership, overseeing data integrity for the advertising business, managing a global team of 200+ individuals, and contributing to the launch of an online education portal that has reached tens of millions of customers. Recognized globally for exceptional sales, he also played a key role in Google X's moonshot initiatives. Seeking cutting-edge developments in science and engineering innovation with the aim of facilitating the transformation of research into viable commercial opportunities. This journey led to his role as a BioDesign Fellow at the Texas Medical Center Innovation Institute in Houston, Texas, incubating Pragma Bio.
Dr. Ginette Serrero is Chief Executive Officer of Precision Antibody, a custom antibody development company, expert in the design, development, characterization and production of monoclonal antibodies for the treatment and diagnosis of human diseases. She draws on biotech management and research expertise in Oncology and biomarker discovery to guide the company's strategy in both the service division and R&D department for the development of biological targeted therapies with companion tissue and serum diagnostics for breast cancer. Her laboratory discovered Progranulin (GP88) as a marker of recurrence, drug resistance and tumor aggressiveness for several cancers including breast and lung cancer. This led to the development of two companion diagnostics that have been clinically validated for disease prognosis and monitoring of breast and lung cancer patients. She is a trained Biochemist with expertise in target discovery, Pharmaceutical Sciences and Oncology. She is Adjunct Professor at the University of Maryland Greenebaum Comprehensive Cancer Center.
She is inventor on several worldwide patents for targets in Oncology and authored 100 peer-reviewed scientific publications and reviews.
Kathy Nevola, PhD (they/them) is a Data Scientist at Olink Proteomics, a Sweden-based provider of advanced protein analysis products and services. As the tool owner and maintainer of Olink’s R package, Olink Analyze, Kathy collaborates with users to uncover biological mechanisms and identify biomarkers within Olink data. Kathy earned their Ph.D. in Cellular, Molecular, and Developmental Biology with a Bioinformatics concentration from Tufts University. Their research focused on exploring potential biological mechanisms associated with beta-blocker use and its protective effects on bone loss, utilizing data from the Framingham Heart study. Outside of work, they enjoy hiking with their dog and partner, practicing yoga, and playing games with friends.
Myles Walsh has extensive experience in the biopharmaceutical industry, with a focus on business development. Myles is Director of BioPharma Business Development at Predicine since March 2022 and prior to this was Senior BioPharma Business Development Manager at Natera focusing on the Signatera MRD assay. Before joining Natera, Myles worked in various BD roles at Sysmex Inostics, Insys Therapeutics, Inc., and Illumina.
His scientific background includes studying the dengue virus at UMass Medical School and working at multiple biotechnology start-ups. Myles attended Worcester Polytechnic Institute where he pursued a Bachelor of Science degree in Biology & Biotechnology.
Ayat stands as a preeminent expert in the specialized realm of biospecimen management, solutions, and chain of custody. With a distinguished career spanning 10+ years, she has consistently showcased an unparalleled dedication to elevating the standards of biospecimen handling and chain of custody management. She has a proven track record of developing and implementing cutting-edge strategies for the collection, storage, and utilization of biospecimens in clinical and research settings. Ayat possesses a profound understanding of the complexities and intricacies involved in biospecimen management, including storage, preservation, and tracking. She is well-versed in adhering to the stringent regulatory and quality guidelines that govern the handling of biospecimens, ensuring compliance with the highest industry standards. What sets Ayat apart is her trailblazing work in driving forward improved processes, solutions, and technologies that enhance the efficiency, integrity, utility, and precision of biospecimen management. Ayat continues to be at the forefront of biospecimen management and solutions, shaping the way biospecimens are collected, stored, and utilized to further scientific discoveries and improve patient outcomes. She is a trusted thought leader in the field and a driving force in promoting the importance of biospecimen management in scientific discoveries, healthcare advancements, and clinical excellence.
Matteo D’Antonio is an assistant project scientist in Kelly Frazer’s lab at UCSD, where is main focus is identifying the molecular mechanisms underlying the associations between genetic variation and disease. He got his Bachelor’s degree in biomedical engineering at Politecnico di Milano in Italy and his Master’s in Bioinformatics at the Technical University of Denmark. After that, he obtained his PhD at the European Institute of Oncology, where he studied the evolution of protein interaction networks and cancer genes. He joined UCSD in 2013 where he transitioned from cancer genomics to human genetics.
Julius Goepp is the founder and CEO of Scaled Microbiomics, LLC, a pre-clinical stage biotech company focused on passive immunotherapy in the microbiome. Dr. Goepp trained in Pediatrics and Emergency Medicine at Children’s Hospital, Boston, and in Pediatric Infectious Disease at Johns Hopkins, where he was active in the promotion of Oral Rehydration Therapy for childhood diarrheal disease. In 2017, he founded Scaled Microbiomics after recognizing the potential for microbiome modulation through the use of little-known avian antibodies, or IgY. Since that time, his energies have been devoted to exploring the characteristics of those antibodies and developing a drug discovery platform based on their use as selective immunomodulators of complex microbiome signaling pathways and event cascades. In addition to his work, Goepp is passionate about cooking, flying, and exploring the outdoors.
Dr. Lapuerta has over 25 years of biotech experience and has led the development and approval of several medicines. He is currently CEO of biotech startup company 4M Therapeutics, developing new treatments in psychiatry and neurology.
Dr. Lapuerta has significant experience in the development and validation of biomarkers and has done research using machine learning to predict clinical outcomes.
He has over 100 scientific publications, including several contributions to the New England Journal of Medicine. He is a graduate of Harvard College and Harvard Medical School.
Nicole Miller is a Scientist and pharmaceutical/biotechnology industry professional with 20+ years experience and leadership in support of Research & Development, Scientific and Molecular Diagnostic Strategy, Newborn Screening and Medical Affairs focusing on ensuring timely, accurate diagnosis and treatment of rare disease.
Carl Saab, MS, MA, PhD, Professor, Department of Biomedical Engineering & Neurological Institute, Cleveland Clinic, Case Western Reserve University and adjunct Professor, Brown University, Department of Engineering.
Scientific Director, Cleveland Clinic Consortium for Pain.
Jiangwei Zhang is a Senior Principal Scientist in Immunology, Cardiovascular & Neurology (ICN) Translational Medicine Team at Bristol Myers Squibb (BMS). He is biomarker lead on several Ozanimod Inflammatory Bowel Disease (IBD) clinical trials and supporting ongoing internal and external Ozanimod IBD collaborative studies. Jiangwei received his PhD from China Agricultural University and did his postdoctoral trainings at University of Texas MD Anderson Cancer Center and Texas A&M Health Science Center on cancer biology. He has worked at Eli Lilly, Ionis Pharmaceuticals and Pfizer in the fibrosis and immunology therapeutic areas prior to joining the Translational Medicine Team at BMS.
Dr. Bornheimer is Associate Director of Medical & Scientific Affairs at BD Biosciences, where he works on the development of new technologies and applications for single cell research, flow cytometry, patient diagnostics, and cell therapy. A major focus is on biomarker and CDx development programs with BioPharma, CROs, and academic medical centers, primarily in oncology and infectious diseases. Previously, he led the R&D effort to develop and commercialize an extremely easy-to-use IVD cytometry system for CD4, %CD4, and Hb measurements for HIV/AIDS patients in resource limited settings (BD FACSPresto). He also led scientific efforts for a COVID-19 diagnostic based on immune cell subsets, co-leads a novel TB diagnostic program, and had leadership roles in developing cell enrichment and isolation technologies based on acoustics, magnetics, and fluorescence-activated cell sorting. He joined BD to apply science and technology to directly impact patient lives, entering through the Technology Leadership Development Program. Dr. Bornheimer received a Ph.D. from UC San Diego in Chemistry and Biochemistry, under joint mentorship in the departments of Cellular and Molecular Medicine and Bioengineering, where he investigated heterotrimeric G-protein signaling through computational modeling, development of new biosensors, and live cell fluorescent imaging approaches.
